Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + cetuximab + FOLFIRI as first-line therapy for unresectable metastatic left-sided RAS/BRAF wild-type colorectal cancer
ChiCTR2000033603Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab, cetuximab and FOLFIRI in colorectal cancer (CRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Started Jun 2020; status: recruiting.
02
Drugs
toripalimabcetuximabFOLFIRI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000033603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033603.